- $137.21m
- -$52.17m
- 10
- 39
- 18
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.83 | ||
| Price to Tang. Book | 0.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -122.7% | ||
| Return on Equity | -81.87% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 174.21 | 325.56 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
Directors
- Rene Russo CHM (46)
- Tillman Gerngross CEO (57)
- Jane Henderson CFO (56)
- David Hering COO (47)
- Rebecca Dabora CTO (62)
- Jill Andersen OTH
- Lynn Connolly OTH (54)
- Elham Hershberger OTH (53)
- Ellen Marram DRC
- Terrance McGuire DRC (65)
- Redonda Miller DRC
- Ajay Royan DRC (41)
- Tomas Heyman IND (65)
- Howard Mayer IND (58)
- Anand Shah IND (41)
- Michael Wyzga IND (66)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 3rd, 2020
- Public Since
- August 6th, 2021
- No. of Shareholders
- 11
- No. of Employees
- 94
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 119,315,787
- Address
- 1601 Trapelo Road, Suite 178, WALTHAM, 02451
- Web
- https://invivyd.com/
- Phone
- +1 7818190080
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for IVVD
Q3 2024 Invivyd Inc Earnings Release
Similar to IVVD
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Invivyd share price?
As of Today at 21:23 UTC, shares in Invivyd are trading at $1.24. This share price information is delayed by 15 minutes.
How has the Invivyd share price performed this year?
Shares in Invivyd last closed at $1.24 and the price had moved by +16.98% over the past 365 days. In terms of relative price strength the Invivyd share price has underperformed the S&P500 Index by -6.92% over the past year.
What are the analyst and broker recommendations for Invivyd?
The overall consensus recommendation for Invivyd is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Invivyd dividend yield?
Invivyd does not currently pay a dividend.
Does Invivyd pay a dividend?
Invivyd does not currently pay a dividend.
When does Invivyd next pay dividends?
Invivyd does not currently pay a dividend.
How do I buy Invivyd shares?
To buy shares in Invivyd you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Invivyd?
As of the previous close price of $1.24, shares in Invivyd had a market capitalisation of $147.95m.
Where are Invivyd shares listed?
Here are the trading details for Invivyd:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: IVVD
What kind of share is Invivyd?
Based on an overall assessment of its quality, value and momentum Invivyd is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Invivyd share price forecast for 2024?
The analyst consensus target price for shares in Invivyd is $9.22. That is 643.55% above the last closing price of $1.24.
Analysts covering Invivyd currently have a consensus Earnings Per Share (EPS) forecast of -$0.88 for the next financial year.
What is the trend in the Invivyd share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Invivyd. Over the past six months, its share price has underperformed the S&P500 Index by -72.08%.
As of the last closing price of $1.24, shares in Invivyd were trading -53.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Invivyd PE Ratio?
The Invivyd PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Invivyd?
Invivyd's management team is headed by:
- Rene Russo - CHM
- Tillman Gerngross - CEO
- Jane Henderson - CFO
- David Hering - COO
- Rebecca Dabora - CTO
- Jill Andersen - OTH
- Lynn Connolly - OTH
- Elham Hershberger - OTH
- Ellen Marram - DRC
- Terrance McGuire - DRC
- Redonda Miller - DRC
- Ajay Royan - DRC
- Tomas Heyman - IND
- Howard Mayer - IND
- Anand Shah - IND
- Michael Wyzga - IND